Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Targeting Cancer Stem Cells

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Sep 12, 2022 10:02am

88 Views

Post# 34956345

RE:RE:RE:RE:RE:Targeting Cancer Stem Cells

Lol, I'm never knowingly correct!

TH1902 wrote: AND WE ARE MOVING UP, IS IT BASED ON THIS POST FROM QWERTY ??? DECENT VOLUME...

TH1902 wrote: First off, thank you for posting Qwerty22, as a non-scientific investor in THERA, this sounds good...sometimes it takes the market time to understand the science from my perspective.

Nice weekend to everyone!!! And thanks to everyone posting on behalf of Thera, because I feel that the company IR is very lacking in getting new investors interested in the story...they can do more imo...SPECEO should steer the board in this direction imo...I don't know how you sit back and tolerate all the mis steps over the years SPECEO... your group needs to apply some pressure...would be happy to discuss...best to all...

qwerty22 wrote:
It reads really well, like all their pre-clinical work. The obvious question is will these findings translate into OBSERVABLE efficacy signals in patients? You have to hope it does.

There are many different ways to go after a cancer indication. One way is to target adjuvant treatment. That's where a drug is given after the primary treatment to stop recurrence. Basically you treat your patients normally in the their primary treatment. Then split the population in two and give one half SOC and the other SOC+TH1902. Success is measured by the % of patients that have their cancer come back. I don't expect they'll do that any time soon, maybe later if they ever get an approval. But this data seems to support this type of approach, mopping up any resistant CSCs left after treatment. Maybe something for a future potential partner/buyer to contemplate.

It's all good stuff, something we are use to in their preclinical work. We need the clinical evidence to unlock the value though.

qwerty22 wrote: Seemed familiar. Looks like it's a full paper version of the poster they presented back in Apr. Maybe there's some new stuff, I'll read it later.

https://aacrjournals.org/cancerres/article/82/12_Supplement/1853/699919